Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of tick-borne encephalitis (TBE) vaccine dosing interval in adults ≥50 years
2011-001348-31Phase 4Active
- Sponsor
- Mälarsjukhuset
- Start
- Apr 2011
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (4 arms), sponsored by Mälarsjukhuset. Primary endpoints: Neutralizing antibody level after second dose (older adults and younger controls) and Neutralizing antibody level after third dose (older adult groups 2 and 3). Started Apr 2011; status: active.
02
Drugs
Tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2011-001348-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001348-31.